ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Byetta & Bydureon

Byetta, Bydureon and Bydureon BCise are injectable drug pens manufactured by AstraZeneca to control blood sugar in people with Type 2 diabetes. They work by signaling the pancreas to make more insulin. People generally tolerate the dugs well, and the most common side effect is nausea. Bydureon and Bydureon BCise have a black box warning for thyroid tumors.

Scientists derived Byetta’s active ingredient, exenatide, from the saliva of the venomous Gila monster found in the southwestern United States. Some patients call the drug “Lizzy” or “Gilly” because of its origin, according to The New York Times. It has become popular with doctors and patients because of its ability to help people lose weight.

“My patients have done strikingly well on the drug,” Dr. Alan J. Garber, of Baylor College of Medicine in Houston, told The Times. “It’s a better choice for an overweight diabetic.”

Manufactured by San Diego-based Amylin Pharmaceuticals, Byetta was approved by the U.S. Food and Drug Administration in 2005. In January 2012, the FDA approved a once-weekly exenatide injection called Bydureon, which is an extended-release version of Byetta.

The FDA had previously rejected Bydureon in 2010 because of evidence that the drug may cause heart rhythm abnormalities. The agency required drug makers to conduct additional safety studies, according to an Amylin press release.

In 2012, Bristol-Myers Squibb purchased Amylin. AstraZeneca acquired the diabetes drug assets from Bristol-Myers Squibb and now markets the Byetta family of medications, which also includes Bydureon BCise, a new injector pen approved in 2017.

Byetta generated $126 million in revenue in 2018 while Bydureon generated $584 million, according to AstraZeneca’s 2018 annual report.

Byetta vs. Bydureon
Bydureon is a longer-lasting version of Byetta and is taken weekly instead of twice a day. It has a black box warning for thyroid tumors while Byetta does not.

According to the Byetta website, the 10 mcg twice daily dose in addition to oral diabetes medications lowered A1C by an average of 0.7 percent to 0.9 percent in people who had started with an A1C of 7.9 percent to 8.6 percent. While exenatide is not a weight loss drug, it also helped people lose between 3.3 pounds and 5.7 pounds in studies that took place over 16 weeks to 30 weeks.

Common Side Effects and Interactions

The medication’s most common side effect is nausea when patients first start therapy. It may lessen over time.

Common side effects include:
  • Nausea
  • Low blood sugar
  • Vomiting
  • Diarrhea
  • Jittery feelings
  • Dizziness
  • Headache
  • Indigestion
  • Constipation
  • Weakness

The drug’s rare and serious side effects include pancreatitis, acute kidney impairment, severe allergic reactions, and Bydureon and Bydureon BCise carry a black box warning for thyroid tumors.

Exenatide may interact with oral medications by slowing their absorption, and there were some reports of bleeding in people who used warfarin with exenatide. Before they take exenatide, women should let their doctor know if they are pregnant or plan to become pregnant.

“Based on animal reproduction studies, there may be risks to the fetus from exposure to Byetta during pregnancy,” according to the medication insert. “Byetta should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”

“Based on animal reproduction studies, there may be risks to the fetus from exposure to Byetta during pregnancy. Byetta should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”

Source: Byetta medication insert

How Does Exenatide Work?

Exenatide is part of a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs mimic the effects of the body’s natural GLP-1, a hormone that reacts to high blood sugar by increasing insulin production.

According to the medication insert, exenatide works to control blood sugar in five ways:
1. Glucose-dependent insulin secretion
Cells in the pancreas that respond to glucose are called beta cells. In studies, Byetta increased the responsiveness of beta cells and allowed for more insulin production. Once sugar levels stabilize, the insulin production stops.
2. First-phase insulin response
The “first-phase insulin response” usually occurs within 10 minutes of taking in glucose. In people with diabetes, defects in the beta cells prevent this first-phase insulin response from occurring. Byetta significantly increased the first-phase and second-phase insulin response in patients with Type 2 diabetes who took the drug during clinical trials.
3. Glucagon secretion
Byetta stops excess glucagon secretion during periods of high blood sugar. Glucagon is a hormone released by the pancreas. It increases blood sugar produced by the liver. By lowering glucagon secretion, the drug makes the liver produce less sugar and lowers the demand for insulin.
4. Gastric emptying
By slowing gastric emptying after meals, Byetta slows the rate at which glucose enters the blood.
5. Lower food intake
Clinical studies for exenatide showed it reduced food intake in animals and humans.

Dosage and Administration

Byetta, Bydureon and Bydureon BCise are all injectable medications, but the dosage and administration instructions may change depending on which one a doctor prescribes. Patients should not share injector pens or needles because they may transmit infections or diseases to themselves or others. Doctors or other health care providers must instruct the patient on how to inject these medications, and each drug comes with detailed directions.

Byetta box and pens
Byetta comes in a prefilled pen with either a 5 mcg or 10 mcg dose taken twice daily. Each prefilled pen delivers a 30-day supply.


Byetta comes in a glass cartridge inside an injector pen. The active ingredient, exenatide, is mixed in water along with a antimicrobial preservative. A health care provider instructs patients on how to inject it in the skin of the upper thigh, stomach or upper arm. Patients should not inject it into a vein or muscle.

The prefilled pen has a 30-day supply of either a 5 mcg or 10 mcg dose taken twice daily. Patients switch out the needle after each use but keep using the same pen for 30 days. The medication insert instructs patients to take Byetta twice a day within 60-minutes before the morning and evening meal or before the two main meals of the day. These two meals must be at least six hours apart.

Patients should take Byetta one hour before the morning and evening meal or before the two main meals of the day, which must be at least six hours apart. Do not take Byetta after eating.
Source: AstraZeneca, How to Take Byetta

Health care providers should start patients on an initial dose of 5 mcg to minimize gastrointestinal side effects. After one month of therapy, the dose can be increased to 10 mcg.

The medication may be prescribed alone or with a sulfonylurea such as Amaryl or Glucotrol; a thiazolidinedione such as Actos or Avandia; metformin; or Lantus, also known as insulin glargine. Doctors may prescribe Byetta with DPP-4 inhibitors like Januvia, but it should not be used in people with Type 1 diabetes.

Bydureon & Bydureon BCise

Bydureon comes in a single-dose tray that contains a vial, a syringe, two needles and a vial connector. This medication is an extended-release formula, so patients only take one shot every seven days. They can do this at any time of day with or without meals.

Assembling the syringe in the single-dose tray takes several steps, so AstraZeneca developed an easier-to-use version called Bydureon BCise. BCise comes in a 2 mg single-use autoinjector pen. Patients inject this formula once a week at any time of day with or without meals. They throw the autoinjector away into a sharps disposal container after each use.

AstraZeneca does not recommend Bydureon or BCise as the first line of treatment for people with Type 2 diabetes, according to the medication insert. People should not use insulin or other forms of exenatide with Bydureon or Bydureon BCise.

Byetta for Weight Loss

Although Byetta is not FDA-approved as a weight loss drug, taking the drug along with making lifestyle changes may help people with Type 2 diabetes lose weight.

In a study published in May 2010 in The American Journal of Medicine, researchers recruited 194 overweight or obese patients with Type 2 diabetes. They gave exenatide to one group and a placebo to the other. Both groups made lifestyle changes.

People who took exenatide lost more weight than those who did not. And according to Amylin’s research, the average amount of weight loss for people who took the drug with another diabetes medication was four pounds over 30 weeks.

Dr. Jody Dushay and other doctors and researchers at Beth Israel Deaconess Medical Center in Boston conducted a study on obese women who did not have diabetes. They published their results in December 2011 in Diabetes Care. They found the women in the study began losing weight in as little as two weeks. After 16 weeks, average weight lost was 5.5 pounds.

While researchers aren’t sure exactly how exenatide helps people lose weight, Dushay and fellow study authors have theories. They say the drug may change the level of energy expenditure or cause nausea, which decreases food intake. But it may also increase leptin sensitivity. Leptin is a hormone that affects hunger and tells people when to stop eating. Obese people have less of a reaction to leptin.

Despite these studies, the FDA has not approved the drug for weight loss, and there are no long-term studies on the safety of exenatide use in people without diabetes.

Byetta Injection Pen
Byetta Facts
  1. Used to Treat Type 2 diabetes
  2. Related Drugs Januvia, Janumet, Victoza, Nesina, Onglyza
  3. Manufacturer Amylin Pharmaceuticals/Astra Zeneca
  4. Black Box Warnings Bydureon and Bydureon BCise for thyroid tumors
  5. FDA Approval Byetta 2005, Bydureon 2012, Bydureon BCise 2017

Please seek the advice of a medical professional before making health care decisions.

Related Pages
Michelle Llamas, Senior Content Writer
Written By Michelle Llamas Senior Writer

Michelle Llamas has been writing articles and producing podcasts about drugs, medical devices and the FDA for nearly a decade. She focuses on various medical conditions, health policy, COVID-19, LGBTQ health, mental health and women’s health issues. Michelle collaborates with experts, including board-certified doctors, patients and advocates, to provide trusted health information to the public. Some of her qualifications include:

  • Member of American Medical Writers Association (AMWA) and former Engage Committee and Membership Committee member
  • Centers for Disease Control and Prevention (CDC) Health Literacy certificates
  • Original works published or cited in The Lancet, British Journal of Clinical Pharmacology and the Journal for Palliative Medicine
Edited By
Emily Miller
Emily Miller Managing Editor
Medically Reviewed By

20 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Apovian, C. M. et al. (2010). Effects of exenatide combined with lifestyle modification in patients with type-2 diabetes. Retrieved from
  2. AstraZeneca. (2018) AstraZeneca Annual Report and Form 20-F Information 2018. Retrieved from
  3. AstraZeneca. (2017, October 23). US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes. Retrieved from
  4. AstraZeneca. (n.d.). Bydureon BCise Instructions for Use. Retrieved from
  5. AstraZeneca. (n.d.). Bydureon BCise. Retrieved from
  6. AstraZeneca. (n.d.). Bydureon Instructions for Use. Retrieved from
  7. AstraZeneca. (n.d.). Considering Byetta. Retrieved from
  8. AstraZeneca. (n.d.). Taking Byetta. Retrieved from
  9. Berenson, A. (2006, March 2).A ray of hope for diabetics. Retrieved from
  10. Byetta 10 mcg picture [Public domain], via Wikimedia Commons
  11. Chiu, W-Y, Shih, S-R, & Tseng, C-H. (2012). A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer. Retrieved from
  12. DailyMed. (2019, July 25). Bydureon BCise. Retrieved from
  13. DailyMed. (2019, February 15). Bydureon. Retrieved from
  14. DailyMed. (2018, December 21). Byetta. Retrieved from
  15. Dushay, J. et al. (2011, December 9). Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes. Retrieved from
  16. Furman, B.L. (2012). The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Retrieved from
  17. Husten, L. (2010, October 19). FDA Issues Complete Response Letter for Bydureon (exenatide-extended release). Retrieved from
  18. U.S. Department of Health and Human Services. (2012, January 27). Division director's memo: Bydureon. Retrieved from
  19. U.S. Food and Drug Administration (FDA). (2015, July 9). Exenatide (marketed as Byetta) information. Retrieved from
  20. U.S. Food and Drug Administration. (2018, February 21). FDA drug safety communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes [Press release]. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(888) 645-1617